Evolocumab Reduces First Major CV Events in Diabetics Without Atherosclerosis

Results from the VESALIUS-CV trial, published on 2026-01-01, indicate that evolocumab reduces first major cardiovascular events in patients with diabetes but without known significant atherosclerosis. This publication highlights a potential benefit for evolocumab in a specific high-risk population.

Background

Evolocumab, also known by its brand name Repatha, is a medication used to lower cholesterol. It is typically prescribed for patients with high cholesterol, particularly those with established cardiovascular disease or familial hypercholesterolemia. The focus of the VESALIUS-CV trial was to investigate the drug's effect in a population at high cardiovascular risk, specifically patients with diabetes who had not experienced a prior myocardial infarction or stroke and did not have known significant atherosclerosis.

Trial design

The VESALIUS-CV trial investigated the effect of evolocumab in patients identified as being at high cardiovascular risk. This population included individuals with diabetes but notably without prior myocardial infarction or stroke, and without known significant atherosclerosis. The primary objective was to assess evolocumab's ability to reduce first major cardiovascular events in this specific patient group.

Key results

The published results from the VESALIUS-CV trial indicate that evolocumab was found to reduce first major cardiovascular events in patients without known significant atherosclerosis and with diabetes.

What this means

The findings from the VESALIUS-CV trial suggest a significant implication for the management of cardiovascular risk in patients with diabetes. For individuals who have diabetes but have not yet experienced a major cardiovascular event or developed significant atherosclerosis, evolocumab may offer a strategy to prevent these initial, critical events. This could expand the utility of evolocumab beyond its current indications, potentially allowing for earlier intervention in a vulnerable patient population to mitigate future cardiovascular complications.

Source

The information regarding the VESALIUS-CV trial results was obtained from a publication on PubMed. The article, titled “Evolocumab to Reduce First Major Cardiovascular Events in Patients Without Known Significant Atherosclerosis and With Diabetes: Results From the VESALIUS-CV Tri (JAMA),” was published on 2026-01-01 on pubmed.ncbi.nlm.nih.gov.